UPDATE: Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2024
0mins
Source: Globenewswire
Virtual Investor Conference Announcement: The Small Cap Growth Virtual Investor Conference held on December 5, 2024, is now available for online viewing, with presentations accessible for 90 days and select companies accepting one-on-one meeting requests until December 10.
About Virtual Investor Conferences: VIC is a leading platform that allows publicly traded companies to present directly to investors, enhancing engagement through interactive features and targeted scheduling.
Analyst Views on IMRN
About IMRN
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), and IMM-529.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
